Insitro

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Ignota Labs is a technology company focused on rescuing failing drugs and bringing new life to abandoned projects, ultimately providing hope to patients. The company utilizes a proprietary AI model, SAFEPATH, which applies deep learning to bioinformatics and cheminformatics datasets to solve drug safety issues. Ignota Labs aims to identify promising drug targets, address safety problems in clinical trials, and accelerate the delivery of therapeutically effective drugs to patients.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

IXICO is a precision analytics company specializing in intelligent insights in neuroscience. They offer a range of services for drug development analytics, imaging operations, and post-marketing consultancy. With a focus on technology and innovation, IXICO provides expertise in imaging biomarkers, radiological reads, volumetric MRI, PET & SPECT, and advanced MRI. Their TrialTracker platform and Assessa tool utilize innovation and AI for disease modeling and analysis. IXICO supports biopharmaceutical companies in CNS clinical research with cutting-edge neuroimaging techniques and AI technology.

SOMA is a Research Automation Platform designed to accelerate medical innovation by automating the process of analyzing medical research articles. It extracts important concepts, identifies causal and associative relationships, and organizes information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like drug repurposing, target discovery, and literature review efficiently. The platform offers API access, community support, and freemium sign-up options.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

PubCompare is a powerful AI-powered tool that helps scientists search, compare, and evaluate experimental protocols. With over 40 million protocols in its database, PubCompare is the largest repository of trusted experimental protocols. PubCompare's AI-powered search features allow users to find similar protocols, highlight critical steps, and evaluate the reproducibility of protocols based on in-protocol citations. PubCompare is available from any computer and requires no download.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Bionl is a no-code bioinformatics platform designed to streamline biomedical research for researchers and scientists. It offers a full workspace with features such as bioinformatics pipelines customization, GenAI for data analysis, AI-powered literature search, PDF analysis, and access to public datasets. Bionl aims to automate cloud, file system, data, and workflow management for efficient and precise analyses. The platform caters to Pharma and Biotech companies, academic researchers, and bioinformatics CROs, providing powerful tools for genetic analysis and speeding up research processes.

Genie TechBio is the world's first AI bioinformatician, offering an LLM-powered omics analysis software that operates entirely in natural language, eliminating the need for coding. Researchers can effortlessly analyze extensive datasets by engaging in a conversation with Genie, receiving recommendations for analysis pipelines, and obtaining results. The tool aims to accelerate biomedical research and empower scientists with newfound data analysis capabilities.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Mapmygenome is an AI-powered platform that offers DNA testing products for health, fitness, and beauty. It provides personalized insights based on genetic analysis to help individuals make informed decisions about their health, wellness, and lifestyle choices. With over 23 years of genomics experience and the latest sequencing technology, Mapmygenome aims to empower users to take proactive steps towards improving their overall well-being.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Cambrian Copilot is an AI tool designed for researchers and engineers to stay updated with the latest machine learning research. It provides access to over 240,000 ML papers, helps in understanding complex details, and automates literature reviews, making the process more efficient and convenient.

Mnemonic AI is an advanced Customer Intelligence tool that offers AI Personas and Digital Twin of the Customer features. It helps organizations of all sizes better understand individuals and tailor messages to their state of mind. The tool creates buyer personas and virtual twins of customers, all 100% data-driven and fully automated. Mnemonic AI also provides OCEAN Personality Analysis, Schwartz Universal Values, and seamless integrations with data sources.

functime is an AI tool designed for time-series machine learning at scale. It provides a comprehensive set of functions and resources for users to perform forecasting tasks efficiently. With features like scoring, ranking, and plotting functions, functime simplifies the evaluation process of thousands of forecasts simultaneously. Additionally, it offers an AI copilot feature to analyze and compare trends, seasonality, and causal factors in forecasts. The tool also includes detailed API reference documentation for seamless integration.

Kolank is an AI tool that offers a unified API for various AI models, including Generative AI. It provides features such as load balancing, fallbacks, cost and performance metrics. Users can easily access and utilize AI models for tasks like generating text, images, and videos. Kolank simplifies the integration of AI capabilities into applications through its user-friendly interface and comprehensive documentation.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.

StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, industry research, and up-to-date data to help users analyze companies and markets more efficiently.

Google Colab Copilot is an AI tool that integrates the GitHub Copilot functionality into Google Colab, allowing users to easily generate code suggestions and improve their coding workflow. By following a simple setup guide, users can start using the tool to enhance their coding experience and boost productivity. With features like code generation, auto-completion, and real-time suggestions, Google Colab Copilot is a valuable tool for developers looking to streamline their coding process.